Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
24
Not yet recruiting, industry sponsors, Immunology and inflammation, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,102
24 trials
Showing 1 to 24, recently updated first.
- Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) CoformulationPivotal-lookingNot yet recruiting
SanofiSanofi (SNY)
NCT07919899 · 150 participants (planned) · Start Nov 30, 2026 · Primary completion May 2, 2028
Drug: Dupilumab coformulated with berahyaluronidase alfa; Dupilumab · For: Dermatitis Atopic
- A Study of Zasocitinib in Adults With Non-pustular Palmoplantar PsoriasisPivotal-lookingNot yet recruiting
TakedaTakeda (TAK)
NCT07752108 · 40 participants (planned) · Start Nov 16, 2026 · Primary completion May 30, 2027
Drug: Zasocitinib · For: Palmoplantar Psoriasis
- A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)Pivotal-lookingNot yet recruiting
TakedaTakeda (TAK)
NCT07871721 · 644 participants (planned) · Start Jan 11, 2027 · Primary completion Apr 18, 2030
Drug: Zasocitinib · For: Psoriatic Arthritis
- A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic DermatitisPivotal-lookingNot yet recruiting
Almirall, S.A.Industry
NCT07873801 · 230 participants (planned) · Start Nov 2026 · Primary completion Feb 2028
Drug: Lebrikizumab; Lebrikizumab and 1 more · For: Atopic Dermatitis
- A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid ArthritisPivotal-lookingNot yet recruiting
Jiankuan (Suzhou) Biotechnology Company LimitedIndustry
NCT07856511 · 590 participants (planned) · Start Oct 15, 2026 · Primary completion Apr 1, 2027
Drug: Placebo; Proximod and 3 more · For: Rheumatoid Arthrits
- Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of AgePivotal-lookingNot yet recruiting
PfizerPfizer (PFE)
NCT07823595 · 90 participants (planned) · Start May 1, 2027 · Primary completion Apr 10, 2029
Drug: Abrocitinib; Placebo · For: Atopic Dermatitis
- Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study CompletersPivotal-lookingNot yet recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07791199 · 2,300 participants (planned) · Start Dec 31, 2026 · Primary completion Oct 31, 2030
Drug: Deucravacitinib · For: Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis and 1 more
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic DermatitisPivotal-lookingNot yet recruiting
Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
NCT07784816 · 390 participants (planned) · Start Aug 31, 2026 · Primary completion Sep 30, 2029
Drug: TLL-018 tablets; TLL-018 tablets and 2 more · For: Atopic Dermatitis (AD)
Sites: Beijing, China
- Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative ColitisPivotal-lookingNot yet recruiting
Ganzhou Hemay Pharmaceutical Co., LtdIndustry
NCT07650942 · 360 participants (planned) · Start Jun 2026 · Primary completion May 2028
Drug: Hemay005 tablet; Placebo and 2 more · For: Ulcerative Colitis (UC)
Sites: Guangzhou, China · 2 sites in all
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.Pivotal-lookingNot yet recruiting
Reistone Biopharma Company LimitedIndustry
NCT07543224 · 600 participants (planned) · Start Apr 2026 · Primary completion Jan 2027
Drug: RSS0393 ointment 0.03%; RSS0393 ointment placebo · For: Plaque Psoriasis Subjects
Sites: Beijing, China
- A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic DermatitisPivotal-lookingNot yet recruiting
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT07540442 · 180 participants (planned) · Start Apr 17, 2026 · Primary completion Jan 5, 2027
Drug: MG-K10 Injection (Humanized Monoclonal Antibody); Placebo for MG-K10 · For: Dermatitis, Atopic
Sites: Shenyang, China
- A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic DermatitisPivotal-lookingNot yet recruiting
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT07479615 · 498 participants (planned) · Start May 1, 2026 · Primary completion Jan 2029
Drug: MG-K10 Humanized Monoclonal Antibody Injection · For: Atopic Dermatitis; Atopic Eczema
- A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type PsoriasisPivotal-lookingNot yet recruiting
Dermavon Holdings LimitedIndustry
NCT07432854 · 540 participants (planned) · Start Mar 3, 2026 · Primary completion Feb 29, 2028
Drug: CMS-D001 50mg; CMS-D001 100mg and 1 more · For: Moderate to Severe Plaque Psoriasis
Sites: Bengbu, China; Wuhu, China; Guangzhou, China · 21 sites in all
- A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic DermatitisPivotal-lookingNot yet recruiting
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT07184645 · 198 participants (planned) · Start Sep 2025 · Primary completion Feb 2027
Drug: OPA-15406; Vehicle · For: Atopic Dermatitis (AD)
Sites: Tokyo, Japan
- A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic DermatitisPivotal-lookingNot yet recruiting
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT07173478 · 156 participants (planned) · Start Oct 2025 · Primary completion Dec 2026
Drug: OPA-15406; Vehicle · For: Atopic Dermatitis (AD)
Sites: Tokyo, Japan
- A Study of Stapokibatrt in Children Subjects With Atopic DermatitisPivotal-lookingNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT07106372 · 240 participants (planned) · Start Sep 2025 · Primary completion Feb 2027
Drug: Stapokibatrt · For: Atopic Dermatitis
Sites: Beijing, China
- Study of Stapokibatrt in Children Subjects With Atopic DermatitisPivotal-lookingNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT06956196 · 240 participants (planned) · Start May 2025 · Primary completion May 2026
Drug: Stapokibatrt · For: Atopic Dermatitis
Sites: Beijing, China
- A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque PsoriasisPivotal-lookingNot yet recruiting
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT06943950 · 500 participants (planned) · Start Jun 1, 2025 · Primary completion Apr 28, 2027
Drug: SYHX1901 · For: Moderate to Severe Plaque Psoriasis
- A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and EfficacyPivotal-lookingNot yet recruiting
Can-Fite BioPharmaIndustry
NCT06643260 · 705 participants (planned) · Start Jun 2025 · Primary completion Dec 2027
Drug: piclidenoson; Placebo · For: Plaque Psoriasis
- A Phase Ⅲ Comparative Study of QL2108 to Dupixent®Pivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06884891 · 520 participants (planned) · Start Apr 2025 · Primary completion May 2027
Drug: QL2108 injection; Dupixent® · For: Atopic Dermatitis
- Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis PatientsPivotal-lookingNot yet recruiting
SFA TherapeuticsIndustry
NCT06863493 · 125 participants (planned) · Start Jun 1, 2025 · Primary completion Jun 1, 2026
Drug: SFA002; Otezla and 1 more · For: Psoriasis (PsO)
- A Study of HS-20137 in Participants with Moderate-to-severe Plaque PsoriasisPivotal-lookingNot yet recruiting
Hansoh BioMedical R&D CompanyIndustry
NCT06844799 · 720 participants (planned) · Start Jun 10, 2025 · Primary completion Mar 31, 2027
Drug: HS-20137; Placebo&HS-20137 · For: Moderate-to-severe Plaque Psoriasis
- The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque PsoriasisPivotal-lookingNot yet recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06833307 · 90 participants (planned) · Start Feb 2025 · Primary completion Jul 2026
Drug: SHR-1314 · For: Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis
Sites: Beijing, China; Shanghai, China
- A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic DermatitisPivotal-lookingNot yet recruiting
AkesoIndustry
NCT06767540 · 198 participants (planned) · Start Jan 23, 2025 · Primary completion Jul 10, 2027
Drug: Placebo; placebo · For: Atopic Dermatitis
Sites: Wuhu, China; Beijing, China; Chongqing, China · 28 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.